Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension

Respiratory Medicine

Volumn 103, Issue 12, 2009, Pages 1801-1806

  Zhang, Jianqiang ^a   Zhang, Ying ^a   Li, Ning ^a   Liu, Zhihong ^a   Xiong, Changming ^a   Ni, Xinhai ^a   Pu, Yaoli ^b   Hui, Rutai ^a   He, Jianguo ^a   Pu, Jielin ^a  

^a FUWAI HOSPITAL   (China)

^b DUKE UNIVERSITY   (United States)

Author keywords

C3 complement; Idiopathic pulmonary arterial hypertension; Leucine rich 2 glycoprotein; Proteomics; RAF1

Indexed keywords

ALBUMIN ISOFORM 2; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; FIBRINOGEN ISOFORM GAMMA A; FIBRINOGEN ISOFORM GAMMA B; HAPTOGLOBIN; HAPTOGLOBIN PRECURSOR; HYDROXYPYRUVATE REDUCTASE ISOFORM 1; LEUCINE RICH A 2 GLYCOPROTEIN; RAF PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART HEMODYNAMICS; HEART OUTPUT; HUMAN; IDIOPATHIC PULMONARY HYPERTENSION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; PULMONARY HYPERTENSION;

ADULT; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; HYPERTENSION, PULMONARY; MALE; PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; YOUNG ADULT;

EID: 70449523330     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.07.017     Document Type: Article

References (28)

1. Rich S., Danzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223 [PubMed: 3605900]
2. Nagaya N., Uematsu M., Satoh T., et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160 (1999) 487-492 [PubMed: 10430718]
3. Torbicki A., Kurzyna M., Kuca P., et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108 (2003) 844-848 [PubMed: 12900346]
4. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 (2001) 1562-1569 [PubMed: 11713135]
5. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870 [PubMed: 10952954]
6. Yi E.S., Kim H., Ahn H., et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162 (2000) 1577-1586 [PubMed:11029379]
7. Cool C.D., Stewart J.S., Werahera P., et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155 (1999) 411-419 [PubMed:10433934]
8. Machado R.D., Pauciulo M.W., Thomson J.R., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68 (2001) 92-102 [PubMed: 11115378]
9. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26 (2000) 81-84 [PubMed: 10973254]
10. Sun D., Kar S., and Carr B.I. Differentially expressed genes in TGF-β1 sensitive and resistant human hepatoma cells. Cancer Lett 89 (1995) 73-79 [PubMed: 7882305]
11. Reimann T., Hempel U., Krautwald S., et al. Transforming growth factor-beta1 induces activation of Ras, Raf-1, MEK and MAPK in rat hepatic stellate cells. FEBS Lett 403 1 (1997 Feb 10) 57-60 [PubMed: 9038360]
12. Bezstarosti K., Das S., Lamers J.M., and Das D.K. Differential proteomic profiling to study the mechanism of cardiac pharmacological preconditioning by resveratrol. J Cell Mol Med 10 4 (2006) 896-907 [PubMed: 17125593]
13. Gallego-Delgado J., Lazaro A., Osende J.I., et al. Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies. J Am Soc Nephrol 17 12 Suppl. 3 (2006) S159-S164 [PubMed: 17130255]
14. Atkinson C., Stewart S., Upton P.D., et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105 14 (2002) 1672-1678 [PubMed: 11940546]
15. Botney M.D., Bahadori L., and Gold L.I. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol 144 2 (1994) 286-295 [PubMed: 8311113]
16. Richter A., Yeager M.E., Zaiman A., et al. Impaired transforming growth Factor β signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 170 12 (2004) 1340-1348 [PubMed: 15361368]
17. Gray M.O., Long C.S., Kalinyak J.E., et al. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40 (1998) 352-363 [PubMed: 9893729]
18. Bujak M., and Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74 (2007) 184-195 [PubMed: 17109837]
19. Matsumoto-Ida M., Takimoto Y., Aoyama T., et al. Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 290 2 (2006) H709-H715 [PubMed: 16183734]
20. Li G., Borger M.A., Williams W.G., et al. Regional overexpression of insulin-like growth factor-I and transforming growth factor-beta1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 123 (2002) 89-95 [PubMed: 11782760]
21. Holweg C.T., Baan C.C., Niesters H.G., et al. TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 20 (2001) 979-984 [PubMed: 11557193]
22. Buono C., Come C.E., Witztum J.L., et al. Influence of C3 deficiency on atherosclerosis. Circulation 105 25 (2002 Jun 25) 3025-3031 [PubMed: 12081998]
23. Barrington R., Zhang M., Fischer M., and Carroll M.C. The role of complement in inflammation and adaptive immunity. Immunol Rev 180 (2001) 5-15 [PubMed: 11414363]
24. Toapanta F.R., and Ross T.M. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36 13 (2006) 197-210 [PubMed: 17337780]
25. Peerschke E.I., Minta J.O., Zhou S.Z., et al. Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Mol Immunol 41 8 (Jul 2004) 759-766 [PubMed: 15234555]
26. Moser K.M., Fedullo P.F., Finkbeiner W.E., et al. Do patients with primary pulmonary hypertension develop extensive central thrombi?. Circulation 91 (1995) 741-745 [PubMed: 7828302]
27. Marshall M.S. Ras target proteins in eukaryotic cells. FASEB J 9 13 (1995) 1311-1318 [PubMed: 7557021]
28. Marais R., and Marshall C.J. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 27 (1996) 101-125 [PubMed: 8909797]